Search PubMed⌕ Search

Biomedical subjects

E Wallen

Publications and source records attributed to E Wallen.

4 recordsLinked to original sources

Brefeldin A induces p53-independent apoptosis in primary cultures of human prostatic cancer cells.

PURPOSE: The objective of this study was to investigate growth-inhibitory and apoptotic activity of the experimental antitumor drug, brefeldin A (BFA), on primary cultures of human epithelial cells derived from prostatic adenocarcinomas. MATERIALS AND METHODS: Clonal assays were performed to evaluate the effects of BFA on growth of prostatic cancer cell strains. Loss of cell viability in response to BFA was assessed by trypan blue exclusion. Induction of apoptosis by BFA was evaluated by morphologic criteria, electrophoretic assay of DNA fragmentation, and a cell death ELISA. Immunoblots were used to monitor p53 and pRB expression in response to BFA. RESULTS: BFA was growth-inhibitory at a half-maximal concentration of 5 ng./ml. (18 nM). Morphological manifestations of apoptosis were evident by 24 hours of treatment. Cell viability declined and the cell death ELISA indicated an 18-fold increase in apoptosis in BFA-treated versus untreated cells at 48 hours. DNA fragmentation was also seen at 48 hours. Levels of p53 were not altered by BFA, but pRB was maintained in a hypophosphorylated state by BFA treatment. CONCLUSIONS: BFA is a potent inducer of apoptosis in prostatic cancer cells via a p53-independent mechanism. Cells derived from low-grade as well as high-grade cancers responded similarly to BFA. Since p53-mediated pathways of apoptosis may frequently be abrogated in prostatic cancer cells, agents such as BFA that induce p53-independent cell death may be promising candidates for chemotherapeutic agents.

Adenocarcinoma↗

Intrahospital transport of critically ill pediatric patients.

OBJECTIVES: To determine the frequency of adverse events during intrahospital transport; to determine the requirement of therapeutic interventions during transport; to test the hypothesis that adverse events that occur during intrahospital transport are due to the transport process itself; and to determine the factors that predict the occurrence of adverse events and the requirement of major therapeutic interventions during transport. DESIGN: A two-phase study in which data were prospectively collected. In phase I, we examined the occurrence rate of adverse events, the requirement for therapeutic interventions, and the factors that predicted adverse events and the requirement of therapeutic interventions. In phase II, we tested the hypothesis that adverse events during transport were due to the transport process itself. SETTING: A 250-bed university children's hospital with a 50-bed intensive care unit (ICU). PATIENTS: Phase I of the study consisted of one hundred and eighty intrahospital transports in 139 patients. These transports included patients who were transferred: a) to the ICU from the operating room, emergency department, or the general ward; b) from the ICU to the operating room; and c) from the ICU for diagnostic or therapeutic procedures. Phase II of the study consisted of 89 transports in 85 patients. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Vital signs and oxygen saturation were measured before and during transport. In phase I, there were no adverse events in 23.9% of transports. There was a significant change in at least one physiologic variable in 71.7% of transports, and at least one equipment-related mishap in 10% of transports. At least one major intervention was performed in 13.9% of transports in response to physiologic deterioration or an equipment-related mishap. There were no arrests or deaths during transport. The requirement for a major procedure was 34.4% in mechanically ventilated patients vs. 9.5% in nonventilated patients. Logistic regression analysis showed that both pretransport Therapeutic Intervention Scoring System and the duration of transport were significantly associated with the requirement of a major intervention and physiologic deterioration, while only the duration of transport was associated with an equipment-related event. The age of the patient and the number of escorts accompanying the transport did not affect the frequency of adverse events. Before transport in phase II study patients, no patient became hypothermic, the changes in physiologic variables were always < 20%, and there was no change > or = 5% in oxygen saturation. Hypothermia occurred in 11.2% of transports. A > or = 20% change in heart rate (15.7%), blood pressure (21.3%), and respiratory rate (23.6%) was seen only during transport. A > 5% change in oxygen saturation (5.6%) was seen only during transport. CONCLUSIONS: Serious physiologic deterioration occurs during intrahospital transport of critically ill children. Severity of illness and the duration of transport are associated with the occurrence of adverse events during transport. The team composition and equipment required on transport must be commensurate with the pretransport severity of illness and the anticipated duration of transport.

Adolescent↗

Sharing the ordeal.

Explore the source record for details and available documents.

Cholecystectomy↗